AMT suspends Glybera and plans 50% job cuts in restructuring moves
This article was originally published in Scrip
Executive Summary
Following a negative opinion from the European Medicine's Agency's Committee for Medicinal Products for Human Use (CHMP) on its lead product, Glybera (alipogene tiparvovec) for the treatment of lipoprotein lipase deficiency (LPLD), Amsterdam Molecular Therapeutics has suspended its programme for the drug and announced a restructure that will reduce the number of full-time employees by a half.